MDxHealth S.A. (MDXH) Stock Ticker
Market factors today
Unlock the full MDXH picture
About MDxHealth S.A.
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
MDXH stock facts
| Ticker symbol | MDXH |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
| Market cap | $29.0M |
| CEO | Michael K. McGarrity |
| Employees | 364 |
| Headquarters | Herstal, WA, BE |
| IPO date | 2021-11-04 |
| Website | mdxhealth.com |
What you can see for MDXH on Tickr
Live MDXH price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the MDXH report.
Rankings
FAQ
What is the ticker symbol for MDxHealth S.A.?
The ticker symbol for MDxHealth S.A. is MDXH, listed on the NASDAQ Capital Market.
What is MDXH?
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive…